In a new proteomics extravaganza, scientists have unearthed groups of proteins that appear to be at the heart of Alzheimer’s disease pathogenesis. As described in Cell on September 25, scientists led ...

Doctor of Philosophy (PhD) University of Pittsburgh, Graduate School of Public Health, Department of Infectious Diseases and Microbiology Graduate Certificate in Public Health Preparedness and ...

The use of blood tests, particularly of p-tau217, in the diagnosis of Alzheimer’s disease has taken off in the last few years, with the number of tests being prescribed now doubling every four to six ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical practice. Now, they are on the cusp. At this year’s ADPD conference, held ...

As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...

1980 Doctor of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. 1980 Master of Sciences, Medical Sciences, Technion - Israel Institute of Technology, Haifa, Israel. 1993 Master of ...

This letter was prompted by your recent perspective paper and the responses it provoked in an Alzforum discussion. Generally, my comments are offered with the intellectual humility required when ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

Not all α-synuclein inclusions are created equal. That’s the upshot from a new stem cell approach to study “inclusionopathies,” such as Parkinson’s and Alzheimer’s diseases. As reported in the ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...